TY - CHAP M1 - Book, Section TI - Anal Cancer A1 - Morris, Van A1 - Crane, Christopher H. A1 - Eng, Cathy A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. Y1 - 2016 N1 - T2 - The MD Anderson Manual of Medical Oncology, 3e AB - Carcinoma of the anal canal is a rare malignancy representing approximately 2.5% of all gastrointestinal malignancies. It is estimated in 2015 that over 7,200 patients will be diagnosed with carcinoma of the anal canal in the United States, resulting in greater than 1,000 deaths (1). The incidence of this disease continues to rise steadily. A practicing oncologist will evaluate and treat less than one such patient per year. The majority of anal carcinoma arises within the mucosa of the anus and is of squamous cell histology (2). Traditionally, 74% to 90% of carcinomas of the anal canal are cured with the combined modalities of chemoradiation, reserving an abdominoperineal resection (APR) for salvage therapy of persistent or recurrent disease (3). This chapter focuses on treatment of squamous cell carcinoma of the anal canal and the potential innovative strategies that lie ahead. SN - PB - McGraw-Hill Medical CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1126742725 ER -